Stability of Antimalarial Preparations Rutendo Kuwana Accra, December 2009.

Slides:



Advertisements
Similar presentations
Dr. Birgit Schmauser, BfArM, Bonn
Advertisements

Slide 1 of 53D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Pogány - Dar es Salaam 1/66 WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence with a focus on artemisinines János Pogány,
Slide 1 of 16 Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community Dar Es.
Finished Pharmaceutical Product Specifications
Stability data required by WHO-PQP Mercy Acquaye.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Experience of Pre-Qualification Program.
Green Chemistry Section 18.5
API Stability Testing WHO PQ Requirements Presented by Rutendo Kuwana Accra, Ghana December 2009.
Evaluation of quality and interchangeability of medicinal products Training workshop for evaluators from National Medicines Regulatory Authorities in East.
Determine impurity level in relevant batches1
INTRODUCTION Related impurities profile and in silico toxicity potential of the anti-malarial drug lumefantrine Sultan Suleman 1, Bram Baert 1, Elien Vangheluwe.
World Health Organization
Dissolution Lynda Paleshnuik
Variations to Prequalified Medicines Rutendo Kuwana Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October 2009.
Choice of antimalarial drugs Malaria Medicines & Supplies Services RBM Partnership Secretariat.
Dr. Pogány - WHO, Bangkok 1/71 QUALITY MANAGEMENT OF ANTIMALARIAL MEDICINES János Pogány, Ph.D., WHO consultant Bangkok, 19 October
Pogány - Guilin 1/57 WHO Training Workshop on Pharmaceutical Quality, G MP and Bioequivalence with a focus on artemisinines János Pogány, pharmacist,
Regulatory requirements on Medicine Stability Guidelines relevant for Stability testing Sultan Ghani.
Slide 1 of 18D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Artemisinin- an innovative cornerstone for anti- malaria therapy 성균관대학교 약학대학 천연물약품화학연구실 석박통합 7 기 김충섭.
Stability Q1(R2). Role Of Stability Safety and efficacy of drug product are established during development via clinical studies Quality is established.
1 TG Dekker – WHO, MalaysiaFeb 2005 Active Pharmaceutical Ingredients (APIs) Workshop on GMP and Quality Assurance of Multisource Tuberculosis Medicines.
| Slide 1 of 33 April 2007 Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Protea Hotel Victoria Junction, Waterfront.
B. AmsdenCHEE 440 Stability The extent to which a product retains, within specified limits, and throughout its period of storage and use, the same properties.
CHEE Stability u the extent to which a product retains, within specified limits, and throughout its period of storage and use, the same properties.
EXTRACTION: solvent partition crude extract hexane-solubles ethyl ether-solubles ethyl acetate-solubles 1-butanol-solubles polar residues water-solubles.
Active pharmaceutical ingredients Presented By Rutendo Kuwana Training workshop: Training workshop on regulatory requirements for registration of Artemisinin.
Theo Dekker -- Jiaxing, China --September |2 | WHO workshop on Quality, good manufacturing practice and bioequivalence with a focus on antituberculotics.
The International Pharmacopoeia Quality standards for TB medicines
Synthetically Engineered Artemisinin Lianne Ryan.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Dossier Requirements for Generic Medicines.
1 TG Dekker – WHO, MalaysiaFeb 2005 Experience with Prequalification of Dossiers (quality part) Workshop on GMP and Quality Assurance of Multisource Tuberculosis.
Carbonyl Compounds I: Chapter 11
Semi-synthetic Artemisinin: A New Source of Artemisinin to Reduce Barriers to ACT Access November 18, 2008 London, UK Presented By Philippe Desjeux, PhD.
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
1 TG Dekker – WHO, UkraineOctober 2005 Introduction to Dossier Requirements and Guidelines within the Prequalification Project (quality part) World Health.
Approval Mechanism for Suppliers of Malaria Drugs and Nets Presentation by Dr Maryse Dugué RBM Partnership Secretariat, Malaria Medicines & Supplies Services.
Quality of Active Pharmaceutical Ingredients, Beijing, March 2010 Tutorial: WHO Prequalification Programme, Maryam MEHMANDOUST Specific quality topics.
The International Pharmacopoeia - The International Pharmacopoeia : One-day Briefing, Geneva | 28 April Overview Caroline Mendy - Technical Officer.
PHC 222 Part(I) Dr. Huda Al Salem
Objectives 1.Structural isomerism: chain, positional, functional, ring-chain, isomerism, metamerism, tautomerism Homologous series 2.Stereoisomerism: conformational,
WHO Workshop on Assessment of Bioequivalence Data Addis Ababa, 31. August – 3. September 2010 Artemisinin-based Products Dr. Henrike Potthast
UN / WHO Prequalification Programme for Priority Medicines
Drug Action and Design IB Chemistry Option D: Drugs and Medicines.
HELM AG Module 3 Christa Clasen Ankara, 6./7. April 2006.
Dar es Salaam, August, 21-25, 2006Dr. Birgit Schmauser, BfArM, Bonn Pharmaceutical Quality Information Form (PQIF) API.
1 Abu Alam Ph.D. Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 23, 2008.
Prequalification of Medicines Program
The International Pharmacopoeia Overview Caroline Mendy Technical Officer - Quality Assurance and Safety: Medicines Quality of Active Pharmaceutical Ingredients,
Pogány - Tanzania 1/36 WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence János Pogány, pharmacist, PhD consultant to.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Pharmaceutical Development Applications.
Dr. Pogány - Geneva 1/30 PREQUALIFICATION OF ANTIMALARIAL DRUG PRODUCTS János Pogány, pharmacist, Ph.D. Geneva, 03 May 2004
Impurities in Drugs author: srikanth N
Dr. Pogány - WHO, Shanghai 1/35 Workshop on Quality Assurance and GMP of Multisource HIV/AIDS medicines János Pogány, pharmacist, PhD, consultant.
Volatile oils Shahana Sharmin Pharmacognosy-II PHR 205.
STABILITY ?.
- Pharmaceutical Equivalence Study
LECTURE LIPIDS   Lipids are natural substances which are insoluble in water, but soluble in non-polar solvents such as hexane, benzene, carbon tetrachloride,
Dr. Birgit Schmauser, BfArM, Bonn
WHO Technical Report Series, No. 953, 2009
Biopharmaceutic Considerations in Drug Product Design
Artemisinin: Discovery from the Chinese Herbal Garden
Quality Problems with Antimalarials
Pharmaceutical Technology I
Alcohols Condensation Reaction CH3 – OH + HO – CH3 CH3 – O – CH3 + H2O
Formulas Molecular formula represents the numbers and types of atoms in a molecule H2O, C6H12O6 Structural formula gives the arrangement of atoms 3-D models.
GL18 (R) – Impurities: Residual Solvents in New Veterinary Medicinal Products, Active Substance and Excipients.
Quality guidelines on impurities
Guideline for Elemental Impurities ICH Q3D(R)
Presentation transcript:

Stability of Antimalarial Preparations Rutendo Kuwana Accra, December 2009

2 |2 | PQ: Artemisin-derivative issues No innovator FPP registered in the ICH region. Therefore No comparator available for: –Pharmaceutical equivalence studies –Bioequivalence studies The APIs and FPPs not official in the internationally used major pharmacopoeias WHO guides/SOPs apply to multisource FPPs. ICH guides therefore used

3 |3 | Expression of Interest – oral dosage forms Artesunate* + Amodiaquine Artemether* + Lumefantrine* Artesunate* + Mefloquine Artesunate* + SP (sulphadoxine / pyrimethamine) Dihydroartemisin+Piperaquine Phosphate* * No comparator at the beginning* High quality-risk API +... FDC or co-blistered (co-packaged) FPPs * No comparator to date

4 |4 | EOI – other dosage forms Artemether Injection and rectal FPPs Artemotil (arteether) Injection Artesunate Injection and rectal FPPs Only FPPs listed in the EOI will be discussed.

5 |5 | Availability of monographs for drug substances - International Pharmacopoeia Artemether Artemisinin Artemotil Artenimol Artesunate Mefloquine Hydrochloride Proguanil Hydrochloride – Also in BP Amodiaquine and Amodiaquine Hydrochloride – Also in USP

6 |6 | International quality standards Lumefantrine Pyrimethamine BP, PhEur, PhInt, USP Sulphadoxine BP, PhEur, PhInt, USP Piperaquine Dihydroartemisinin

7 |7 | Other Antimalarial API –APIs described in monographs of major international pharmacopoeias (  10 years) Chloroquine, Dapsone, Quinine, Mefloquine, Trimethoprim –APIs not described in monographs of major international pharmacopoeias Chlorproguanil,, Naphthoquine, Pyronaridine

8 |8 | Properties of Artemisinin derivatives Artemisinin (C 15 H 22 O 5 ) –7 centres of asymmetry –2 7 potential isomers –One isomer in biosynthesis –Chemical synthesis Feasible Economically unacceptable Chemical derivatization at C-10 (carbonyl-moiety) converts C-10 into an additional stereoisomeric center:  - and  -isomers are formed a 8a a

9 |9 | Artemisinin Active antimalarial constituent of the traditional Chinese medicinal herb Artemisia annua L., Compositae Although Artemisinin has seven (7) centers of assymetry Artemisia annua makes only one configuration Practically insoluble in water The bond energy of the O-O bond is ~30 kcal/mol When the peroxide comes into contact with high iron concentrations, the molecule becomes unstable and "explodes" into free radicals. The API, the capsules and the tablets are official in the Ph. Int. Not included in the current EOI.

10 | Artesunate Very slightly soluble in water The ester linkage is in alpha configuration. Both the API and the tablets are official in the Ph. Int. Two functional groups are liable to decomposition

11 | Metabolism of Artemether and Artesunate

12 | Mefloquine hydrochloride Has an optically active carbon Very slightly soluble in water Has no reactive functional groups under general environmental conditions

13 | Pharmaceutical information Artemisinin derivatives may have α- or β-configuration and each of them can exist in two conformations. The literature does not reveal any impact of the geometric isomerism on efficacy, safety or quality of artemisinins. The internal peroxide bound is the most reactive part of the molecule. When the peroxide comes into contact with high iron concentrations, the molecule becomes unstable and "explodes" into free radicals. The ester bond of artesunate is liable to hydrolysis. The non-artemisinin APIs in the EoI are chemically stable.

14 | Potential impurities of Artemisinins Starting material (extracted from herbal sources) Starting materials from vegetable origin should be fully characterized and a contaminant profile should be established

15 | Potential impurities of Artemisinins II Impurities contained in the "starting material" Artemisinin –Biosynthetic by-products Arteannuin B, Artemisitene, Artemisinic acid, –Extraction from fresh leaves with CHCl 3 Thujone (?) –Cultivation reagents Pesticide residues, fumigants, mycotoxins –Solvents from the extraction process Hexane, benzene, acetonitril, ether, pentane, chloroforme…..(?) diesel, fuel (?) [ICH Q3A (R)]

16 | Potential impurities of Artemisinins III Unreacted starting material –Artemisinin (starting material for derivatives) –Artemisinic acid (starting material for dihydroartemisinin) –Dihydroartemisinin (starting material for derivatives) –…. Unreacted intermediates, by-products –  -Arthemether,  -Artheether –  /  -Dihydroartemisinin –  -Artesunate

17 | Potential impurities of Artemisinins IV Reagents, catalysts, residual solvents –Methanol, acetonitril, chloroforme, acetone … –NaBH 4, succinic acid/anhydride, triethylamine, dimethylaminopyridine Degradants –Stability of ester-derivative (Artesunate) ether-derivative (Artemether, Arteether) lactone (Artemisinin) –Stability of artenimol (oxidation) –Susceptibility of endoperoxide bond to reduction Deoxyartemisinine (loss of active principle)

18 | Compatibility of the API with excipients and diluents Select innovator excipients ( WHOPAR, EPAR ) Magnesium stearate is incompatible with salts of weak bases and strong acids (e.g. Amodiaquine.2HCl) because the formed MgCl 2 is highly hygroscopic and, as a result, its lubricant properties also change. The compatibility and in-use stability of the FPP with reconstitution diluents should be addressed, e.g. in Artesunate injection.

19 | Increase in concentration of API During some stability studies of Artesunate, the assay results were increasing. The hydrolysis may yield artenimol and succinic acid. The latter can justify the increase in assay. The assay method may be considered to be "stability indicating” but not specific. +

20 | Stress Testing Artesunate The drug substance degrades readily at heat conditions in extreme of 100ºC, it is also unstable under light conditions and both acid and base conditions by hydrolysis. The α-epimer of dihydroartemesinin is the major degradant under light conditions. α-Artemether is the major degradant under heat conditions in extreme of 100ºC although both the α and ß epimers of dihydroartemesinin are also significant degradants under this condition.